Acorda Therapeutics Inc. (NASDAQ: ACOR) shares dipped on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) would be delaying its Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Inbrija.
The FDA is moving the PDUFA date back to January 5, 2019, from the previous date of October 5, 2018.
This extension is related to recent submissions Acorda made in response to requests from FDA for additional information on chemistry, manufacturing and controls. FDA determined that these submissions constitute a major amendment and will take additional time to review.
Previously, the FDA accepted Acorda’s NDA for Inbrija in February 2018.
Ron Cohen, M.D., Acorda’s president and chief executive, commented:
We look forward to continuing our constructive dialogue with FDA. We remain committed to bringing INBRIJA to approval for people with Parkinson’s who experience OFF periods, which are highly disruptive and in need of new therapeutic options.
Excluding Thursday’s move, Acorda has underperformed the broad markets, with the stock down 20% in the past 52 weeks. In just 2018 alone, the stock is down closer to 14%.
Shares of Acorda were last seen down 12% at $16.30, with a consensus analyst price target of $27.00 and a 52-week range of $15.60 to $36.35.
24/7 Wall St.Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
